FINWIRES · TerminalLIVE
FINWIRES

瑞銀表示,百勝餐飲集團旗下品牌在塔可鐘和肯德基的支持下勢頭強勁。

-- 瑞銀證券週三發布的一份報告指出,百勝餐飲集團(YUM)預計將繼續保持成長勢頭,這主要得益於塔可鐘和肯德基的強勁成長勢頭。即使面臨惡劣天氣、燃料成本上漲、地緣政治衝突以及消費者支出疲軟等壓力,百勝的績效指引仍可能維持不變。 報告稱,塔可鐘有望成為第一季的主要成長動力,這得益於其超值產品、新菜單、行銷以及數位化需求的成長。瑞銀也表示,塔可鐘豐富的產品線和不斷擴張的飲品平台也將為其帶來收益,而「Live Mas Cafe」計畫被視為另一個未來多年的銷售成長點。 報告指出,肯德基預計也將保持穩健的成長勢頭,這主要得益於其在英國和亞洲市場的強勁表現。儘管面臨激烈的市場競爭,肯德基在美國的業務似乎也逐漸改善。 報告稱,在塔可鐘新店開業以及肯德基在印度和中國的發展計劃的推動下,門市數量增長應會保持穩健,但必勝客潛在的關店潮可能會抵消部分擴張勢頭。 報告稱,百勝餐飲集團的核心品牌預計在未來支撐更快的獲利成長,而投資人則關注必勝客的評估以及Byte平台的最新進展。 瑞銀維持對百勝餐飲集團股票的「買入」評級,目標價為180美元。 第一季業績將於4月29日公佈。

Price: $159.41, Change: $-0.94, Percent Change: -0.58%

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA